ATAI
program indication preclinical phase phase phase affiliate company treatment resistant depression compound cognitive impairment associated with schizophrenia generalized anxiety disorder treatment resistant depression use disorder use disorder derivative post traumatic stress disorder treatment resistant depression post traumatic stress disorder anorexia limited to equity interest perception life sciences therapeutics life sciences compass pathways compass pathways compass pathways we will deliver on our strategy through a robust pipeline drug development programs across several mental health indications large unmet need | ATAI
Company
Deck date
October 2022
Slide
6 of 41
Similar slides by ATAI
Investor Presentation
October 2023
Investor Conference
May 2023
Investor Presentation
April 2023
Investor Presentation
March 2023
Related slides by other companies
Investor Presentation
May 2023
Investor Presentation
March 2023
Investor Presentation
November 2023
Investor Presentation
September 2023
Other recent decks by ATAI
Investor Presentation
January 2024
Investor Presentation
October 2023
Investor Conference
May 2023
Investor Presentation
April 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io